Skip to main content
Clinical Trials/NCT03251521
NCT03251521
Completed
Not Applicable

Evaluation of Pain Intensity in Different Steps of Injection With Botulinum Toxin in the Treatment of Spasticity in Post-stroke Patients

University Hospital, Grenoble0 sites46 target enrollmentMarch 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post-stroke Spasticity
Sponsor
University Hospital, Grenoble
Enrollment
46
Primary Endpoint
Evolution of pain intensity during injection with botulinum toxin
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The aim of the study was to analyze which step of the procedure of toxin botulinum injection is the most painful between skin break-in, electric stimulation, injection and needle withdrawal.

Detailed Description

Post-stroke spasticity management by botulinum toxin injections may be limited by pain or discomfort at the injection side. Particularly tracking by electrostimulation, but also skin puncture, toxin injection or needle withdrawal may be painful. The objective of this study is to define an individual injection strategy in order to limit pain.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
July 2013
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Grenoble
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • severe upper or lower limb spasticity (Ashworth score ≥ 2 for at least one muscle)
  • patients requiring a treatment by botulinum toxin
  • patients refusing analgesia for injections.

Exclusion Criteria

  • severe aphasia (severity subscore of the BDAE \<3)
  • cognitive impairment or psychiatric disease altering the reliability of pain evaluation
  • patient medically unstable.

Outcomes

Primary Outcomes

Evolution of pain intensity during injection with botulinum toxin

Time Frame: 30 min

Pain intensity in different steps of the procedure of toxin botulinum injection: skin break-in, electric stimulation, injection and needle withdrawal.

Secondary Outcomes

  • Hypoesthesia(30 min)
  • Neuropathic pain(30 min)

Similar Trials